# REPL — Replimune Group Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** REPL  
**Sources:** 22  
**Published:** 2026-08-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-repl-replimune-group-inc-catalysts-narrative-risks-1427

---

# Replimune Group, Inc. (NASDAQ: REPL) — Research as of 2026-10-14

**On reading the sources critically:** REPL is a clinical-stage biotech whose share price is highly sensitive to binary regulatory outcomes and earnings reports — the kind of fundamental events that quantitative-markets studies identify as major price drivers [LIB-1], [LIB-3]. Because such events tend to generate strong one-directional coverage, I cross-checked the regulatory, financial, and litigation materials below against one another. Note that some items come from law-firm press releases that are recruitment materials, so their claims are "alleged," not adjudicated.

## 1. Recent catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-repl-replimune-group-inc-catalysts-narrative-risks-1427 (free to sign up)._
